NAVIDEA BIOPHARMACEUTICALS, INC.
DelistedCIK 810509fmd_0QXF3FW726K0BVVWRQQH6VG8S8Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2023, 55 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 2 | 3 | 5 | 2 | 1 | 1 | 1 | 1 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | (3) | (3) | (1) | (0) | 0 | (0) | – | – | – | – |
| Gross profit | 1 | 2 | 3 | 5 | 2 | 1 | 1 | 1 | 1 | (0) |
| Research and development | 24 | 15 | 11 | 7 | 5 | 4 | 5 | 5 | 5 | 6 |
| Selling, general and administrative | 16 | 10 | 11 | 8 | 11 | 8 | 6 | 7 | 7 | 8 |
| Total operating expenses | 39 | 25 | 21 | 15 | 16 | 12 | 12 | 12 | 13 | 14 |
| Operating income | (38) | (23) | (18) | (10) | (14) | (11) | (11) | (11) | (12) | (14) |
| Interest expense | 3 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | (4) | (8) | 0 | (0) | (0) | 0 | (0) | (0) | (0) | (0) |
| Income before taxes | (43) | (30) | (23) | (7) | (18) | (16) | (11) | (11) | (12) | (15) |
| Income tax expense | 0 | 0 | (0) | 0 | (4) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (43) | (36) | (23) | (7) | (14) | (16) | (11) | (11) | (12) | (15) |
| Net income | (43) | (36) | (28) | (14) | 75 | (16) | (11) | (11) | (12) | (15) |
| Net income to common shareholders | (43) | (36) | (28) | (14) | 75 | (16) | (11) | (11) | (12) | (17) |